Non-small Cell Lung Cancer Therapeutics
The global Non-small Cell Lung Cancer Therapeutics market was valued at 611.2 Million USD in 2021 and will grow with a CAGR of 7% from 2021 to 2027, based on HNY Research newly published report.
The prime objective of this report is to provide the insights on the post COVID-19 impact wwhich will help market players in this field evaluate their business approaches. Also, this report covers market segmentation by major market verdors, types, applications/end users and geography(North America, East Asia, Europe, South Asia, Southeast Asia, Middle East, Africa, Oceania, South America).
Non-small-cell lung carcinoma (NSCLC) is any type of epithelial lung cancer other than small cell lung carcinoma (SCLC). NSCLC accounts for about 85% of all lung cancers.
By Market Verdors
GlaxoSmithKline
Novartis
AstraZeneca
Roche
Bristol-Myers Squibb
Pfizer
Eli Lilly
Sanofi
By Types
Alimta
Iressa
Avastin
Tarceva
Zykadia
Tagrisso
Xalkori
Cyramza
Opdivo
By Applications
Hospital
Clinic
Key Indicators Analysed
Market Players & Competitor AnalysisThe report covers the key players of the industry including Company Profile, Product Specifications, Production Capacity/Sales, Revenue, Price and Gross Margin 2016-2027 & Sales with a thorough analysis of the market’s competitive landscape and detailed information on vendors and comprehensive details of factors that will challenge the growth of major market vendors.
Global and Regional Market AnalysisThe report includes Global & Regional market status and outlook 2016-2027. Further the report provides break down details about each region & countries covered in the report. Identifying its sales, sales volume & revenue forecast. With detailed analysis by types and applications.
Market TrendsMarket key trends which include Increased Competition and Continuous Innovations.
Opportunities and DriversIdentifying the Growing Demands and New Technology
Porters Five Force AnalysisThe report provides with the state of competition in industry depending on five basic forcesthreat of new entrants, bargaining power of suppliers, bargaining power of buyers, threat of substitute products or services, and existing industry rivalry.
Key Reasons to Purchase
To gain insightful analyses of the market and have comprehensive understanding of the global market and its commercial landscape.
Assess the production processes, major issues, and solutions to mitigate the development risk.
To understand the most affecting driving and restraining forces in the market and its impact in the global market.
Learn about the market strategies that are being adopted by leading respective organizations.
To understand the future outlook and prospects for the market.
Besides the standard structure reports, we also provide custom research according to specific requirements
Table of Content
1 Report Overview
1.1 Study Scope
1.2 Key Market Segments
1.3 Players Covered: Ranking by Non-small Cell Lung Cancer Therapeutics Revenue
1.4 Market Analysis by Type
1.4.1 Global Non-small Cell Lung Cancer Therapeutics Market Size Growth Rate by Type: 2021 VS 2027
1.4.2 Alimta
1.4.3 Iressa
1.4.4 Avastin
1.4.5 Tarceva
1.4.6 Zykadia
1.4.7 Tagrisso
1.4.8 Xalkori
1.4.9 Cyramza
1.4.10 Opdivo
1.5 Market by Application
1.5.1 Global Non-small Cell Lung Cancer Therapeutics Market Share by Application: 2022-2027
1.5.2 Hospital
1.5.3 Clinic
1.6 Study Objectives
1.7 Years Considered
1.8 Overview of Global Non-small Cell Lung Cancer Therapeutics Market
1.8.1 Global Non-small Cell Lung Cancer Therapeutics Market Status and Outlook (2016-2027)
1.8.2 North America
1.8.3 East Asia
1.8.4 Europe
1.8.5 South Asia
1.8.6 Southeast Asia
1.8.7 Middle East
1.8.8 Africa
1.8.9 Oceania
1.8.10 South America
1.8.11 Rest of the World
2 Market Competition by Manufacturers
2.1 Global Non-small Cell Lung Cancer Therapeutics Production Capacity Market Share by Manufacturers (2016-2021)
2.2 Global Non-small Cell Lung Cancer Therapeutics Revenue Market Share by Manufacturers (2016-2021)
2.3 Global Non-small Cell Lung Cancer Therapeutics Average Price by Manufacturers (2016-2021)
2.4 Manufacturers Non-small Cell Lung Cancer Therapeutics Production Sites, Area Served, Product Type
3 Sales by Region
3.1 Global Non-small Cell Lung Cancer Therapeutics Sales Volume Market Share by Region (2016-2021)
3.2 Global Non-small Cell Lung Cancer Therapeutics Sales Revenue Market Share by Region (2016-2021)
3.3 North America Non-small Cell Lung Cancer Therapeutics Sales Volume
3.3.1 North America Non-small Cell Lung Cancer Therapeutics Sales Volume Growth Rate (2016-2021)
3.3.2 North America Non-small Cell Lung Cancer Therapeutics Sales Volume Capacity, Revenue, Price and Gross Margin (2016-2021)
3.4 East Asia Non-small Cell Lung Cancer Therapeutics Sales Volume
3.4.1 East Asia Non-small Cell Lung Cancer Therapeutics Sales Volume Growth Rate (2016-2021)
3.4.2 East Asia Non-small Cell Lung Cancer Therapeutics Sales Volume Capacity, Revenue, Price and Gross Margin (2016-2021)
3.5 Europe Non-small Cell Lung Cancer Therapeutics Sales Volume (2016-2021)
3.5.1 Europe Non-small Cell Lung Cancer Therapeutics Sales Volume Growth Rate (2016-2021)
3.5.2 Europe Non-small Cell Lung Cancer Therapeutics Sales Volume Capacity, Revenue, Price and Gross Margin (2016-2021)
3.6 South Asia Non-small Cell Lung Cancer Therapeutics Sales Volume (2016-2021)
3.6.1 South Asia Non-small Cell Lung Cancer Therapeutics Sales Volume Growth Rate (2016-2021)
3.6.2 South Asia Non-small Cell Lung Cancer Therapeutics Sales Volume Capacity, Revenue, Price and Gross Margin (2016-2021)
3.7 Southeast Asia Non-small Cell Lung Cancer Therapeutics Sales Volume (2016-2021)
3.7.1 Southeast Asia Non-small Cell Lung Cancer Therapeutics Sales Volume Growth Rate (2016-2021)
3.7.2 Southeast Asia Non-small Cell Lung Cancer Therapeutics Sales Volume Capacity, Revenue, Price and Gross Margin (2016-2021)
3.8 Middle East Non-small Cell Lung Cancer Therapeutics Sales Volume (2016-2021)
3.8.1 Middle East Non-small Cell Lung Cancer Therapeutics Sales Volume Growth Rate (2016-2021)
3.8.2 Middle East Non-small Cell Lung Cancer Therapeutics Sales Volume Capacity, Revenue, Price and Gross Margin (2016-2021)
3.9 Africa Non-small Cell Lung Cancer Therapeutics Sales Volume (2016-2021)
3.9.1 Africa Non-small Cell Lung Cancer Therapeutics Sales Volume Growth Rate (2016-2021)
3.9.2 Africa Non-small Cell Lung Cancer Therapeutics Sales Volume Capacity, Revenue, Price and Gross Margin (2016-2021)
3.10 Oceania Non-small Cell Lung Cancer Therapeutics Sales Volume (2016-2021)
3.10.1 Oceania Non-small Cell Lung Cancer Therapeutics Sales Volume Growth Rate (2016-2021)
3.10.2 Oceania Non-small Cell Lung Cancer Therapeutics Sales Volume Capacity, Revenue, Price and Gross Margin (2016-2021)
3.11 South America Non-small Cell Lung Cancer Therapeutics Sales Volume (2016-2021)
3.11.1 South America Non-small Cell Lung Cancer Therapeutics Sales Volume Growth Rate (2016-2021)
3.11.2 South America Non-small Cell Lung Cancer Therapeutics Sales Volume Capacity, Revenue, Price and Gross Margin (2016-2021)
3.12 Rest of the World Non-small Cell Lung Cancer Therapeutics Sales Volume (2016-2021)
3.12.1 Rest of the World Non-small Cell Lung Cancer Therapeutics Sales Volume Growth Rate (2016-2021)
3.12.2 Rest of the World Non-small Cell Lung Cancer Therapeutics Sales Volume Capacity, Revenue, Price and Gross Margin (2016-2021)
4 North America
4.1 North America Non-small Cell Lung Cancer Therapeutics Consumption by Countries
4.2 United States
4.3 Canada
4.4 Mexico
5 East Asia
5.1 East Asia Non-small Cell Lung Cancer Therapeutics Consumption by Countries
5.2 China
5.3 Japan
5.4 South Korea
6 Europe
6.1 Europe Non-small Cell Lung Cancer Therapeutics Consumption by Countries
6.2 Germany
6.3 United Kingdom
6.4 France
6.5 Italy
6.6 Russia
6.7 Spain
6.8 Netherlands
6.9 Switzerland
6.10 Poland
7 South Asia
7.1 South Asia Non-small Cell Lung Cancer Therapeutics Consumption by Countries
7.2 India
7.3 Pakistan
7.4 Bangladesh
8 Southeast Asia
8.1 Southeast Asia Non-small Cell Lung Cancer Therapeutics Consumption by Countries
8.2 Indonesia
8.3 Thailand
8.4 Singapore
8.5 Malaysia
8.6 Philippines
8.7 Vietnam
8.8 Myanmar
9 Middle East
9.1 Middle East Non-small Cell Lung Cancer Therapeutics Consumption by Countries
9.2 Turkey
9.3 Saudi Arabia
9.4 Iran
9.5 United Arab Emirates
9.6 Israel
9.7 Iraq
9.8 Qatar
9.9 Kuwait
9.10 Oman
10 Africa
10.1 Africa Non-small Cell Lung Cancer Therapeutics Consumption by Countries
10.2 Nigeria
10.3 South Africa
10.4 Egypt
10.5 Algeria
10.6 Morocco
11 Oceania
11.1 Oceania Non-small Cell Lung Cancer Therapeutics Consumption by Countries
11.2 Australia
11.3 New Zealand
12 South America
12.1 South America Non-small Cell Lung Cancer Therapeutics Consumption by Countries
12.2 Brazil
12.3 Argentina
12.4 Columbia
12.5 Chile
12.6 Venezuela
12.7 Peru
12.8 Puerto Rico
12.9 Ecuador
13 Rest of the World
13.1 Rest of the World Non-small Cell Lung Cancer Therapeutics Consumption by Countries
13.2 Kazakhstan
14 Sales Volume, Sales Revenue, Sales Price Trend by Type
14.1 Global Non-small Cell Lung Cancer Therapeutics Sales Volume Market Share by Type (2016-2021)
14.2 Global Non-small Cell Lung Cancer Therapeutics Sales Revenue Market Share by Type (2016-2021)
14.3 Global Non-small Cell Lung Cancer Therapeutics Sales Price by Type (2016-2021)
15 Consumption Analysis by Application
15.1 Global Non-small Cell Lung Cancer Therapeutics Consumption Volume by Application (2016-2021)
15.2 Global Non-small Cell Lung Cancer Therapeutics Consumption Value by Application (2016-2021)
16 Company Profiles and Key Figures in Non-small Cell Lung Cancer Therapeutics Business
16.1 GlaxoSmithKline
16.1.1 GlaxoSmithKline Company Profile
16.1.2 GlaxoSmithKline Non-small Cell Lung Cancer Therapeutics Product Specification
16.1.3 GlaxoSmithKline Non-small Cell Lung Cancer Therapeutics Production Capacity, Revenue, Price and Gross Margin (2016-2021)
16.2 Novartis
16.2.1 Novartis Company Profile
16.2.2 Novartis Non-small Cell Lung Cancer Therapeutics Product Specification
16.2.3 Novartis Non-small Cell Lung Cancer Therapeutics Production Capacity, Revenue, Price and Gross Margin (2016-2021)
16.3 AstraZeneca
16.3.1 AstraZeneca Company Profile
16.3.2 AstraZeneca Non-small Cell Lung Cancer Therapeutics Product Specification
16.3.3 AstraZeneca Non-small Cell Lung Cancer Therapeutics Production Capacity, Revenue, Price and Gross Margin (2016-2021)
16.4 Roche
16.4.1 Roche Company Profile
16.4.2 Roche Non-small Cell Lung Cancer Therapeutics Product Specification
16.4.3 Roche Non-small Cell Lung Cancer Therapeutics Production Capacity, Revenue, Price and Gross Margin (2016-2021)
16.5 Bristol-Myers Squibb
16.5.1 Bristol-Myers Squibb Company Profile
16.5.2 Bristol-Myers Squibb Non-small Cell Lung Cancer Therapeutics Product Specification
16.5.3 Bristol-Myers Squibb Non-small Cell Lung Cancer Therapeutics Production Capacity, Revenue, Price and Gross Margin (2016-2021)
16.6 Pfizer
16.6.1 Pfizer Company Profile
16.6.2 Pfizer Non-small Cell Lung Cancer Therapeutics Product Specification
16.6.3 Pfizer Non-small Cell Lung Cancer Therapeutics Production Capacity, Revenue, Price and Gross Margin (2016-2021)
16.7 Eli Lilly
16.7.1 Eli Lilly Company Profile
16.7.2 Eli Lilly Non-small Cell Lung Cancer Therapeutics Product Specification
16.7.3 Eli Lilly Non-small Cell Lung Cancer Therapeutics Production Capacity, Revenue, Price and Gross Margin (2016-2021)
16.8 Sanofi
16.8.1 Sanofi Company Profile
16.8.2 Sanofi Non-small Cell Lung Cancer Therapeutics Product Specification
16.8.3 Sanofi Non-small Cell Lung Cancer Therapeutics Production Capacity, Revenue, Price and Gross Margin (2016-2021)
17 Non-small Cell Lung Cancer Therapeutics Manufacturing Cost Analysis
17.1 Non-small Cell Lung Cancer Therapeutics Key Raw Materials Analysis
17.1.1 Key Raw Materials
17.2 Proportion of Manufacturing Cost Structure
17.3 Manufacturing Process Analysis of Non-small Cell Lung Cancer Therapeutics
17.4 Non-small Cell Lung Cancer Therapeutics Industrial Chain Analysis
18 Marketing Channel, Distributors and Customers
18.1 Marketing Channel
18.2 Non-small Cell Lung Cancer Therapeutics Distributors List
18.3 Non-small Cell Lung Cancer Therapeutics Customers
19 Market Dynamics
19.1 Market Trends
19.2 Opportunities and Drivers
19.3 Challenges
19.4 Porter's Five Forces Analysis
20 Production and Supply Forecast
20.1 Global Forecasted Production of Non-small Cell Lung Cancer Therapeutics (2022-2027)
20.2 Global Forecasted Revenue of Non-small Cell Lung Cancer Therapeutics (2022-2027)
20.3 Global Forecasted Price of Non-small Cell Lung Cancer Therapeutics (2016-2027)
20.4 Global Forecasted Production of Non-small Cell Lung Cancer Therapeutics by Region (2022-2027)
20.4.1 North America Non-small Cell Lung Cancer Therapeutics Production, Revenue Forecast (2022-2027)
20.4.2 East Asia Non-small Cell Lung Cancer Therapeutics Production, Revenue Forecast (2022-2027)
20.4.3 Europe Non-small Cell Lung Cancer Therapeutics Production, Revenue Forecast (2022-2027)
20.4.4 South Asia Non-small Cell Lung Cancer Therapeutics Production, Revenue Forecast (2022-2027)
20.4.5 Southeast Asia Non-small Cell Lung Cancer Therapeutics Production, Revenue Forecast (2022-2027)
20.4.6 Middle East Non-small Cell Lung Cancer Therapeutics Production, Revenue Forecast (2022-2027)
20.4.7 Africa Non-small Cell Lung Cancer Therapeutics Production, Revenue Forecast (2022-2027)
20.4.8 Oceania Non-small Cell Lung Cancer Therapeutics Production, Revenue Forecast (2022-2027)
20.4.9 South America Non-small Cell Lung Cancer Therapeutics Production, Revenue Forecast (2022-2027)
20.4.10 Rest of the World Non-small Cell Lung Cancer Therapeutics Production, Revenue Forecast (2022-2027)
20.5 Forecast by Type and by Application (2022-2027)
20.5.1 Global Sales Volume, Sales Revenue and Sales Price Forecast by Type (2022-2027)
20.5.2 Global Forecasted Consumption of Non-small Cell Lung Cancer Therapeutics by Application (2022-2027)
21 Consumption and Demand Forecast
21.1 North America Forecasted Consumption of Non-small Cell Lung Cancer Therapeutics by Country
21.2 East Asia Market Forecasted Consumption of Non-small Cell Lung Cancer Therapeutics by Country
21.3 Europe Market Forecasted Consumption of Non-small Cell Lung Cancer Therapeutics by Countriy
21.4 South Asia Forecasted Consumption of Non-small Cell Lung Cancer Therapeutics by Country
21.5 Southeast Asia Forecasted Consumption of Non-small Cell Lung Cancer Therapeutics by Country
21.6 Middle East Forecasted Consumption of Non-small Cell Lung Cancer Therapeutics by Country
21.7 Africa Forecasted Consumption of Non-small Cell Lung Cancer Therapeutics by Country
21.8 Oceania Forecasted Consumption of Non-small Cell Lung Cancer Therapeutics by Country
21.9 South America Forecasted Consumption of Non-small Cell Lung Cancer Therapeutics by Country
21.10 Rest of the world Forecasted Consumption of Non-small Cell Lung Cancer Therapeutics by Country
22 Research Findings and Conclusion
23 Methodology and Data Source
23.1 Methodology/Research Approach
23.1.1 Research Programs/Design
23.1.2 Market Size Estimation
23.1.3 Market Breakdown and Data Triangulation
23.2 Data Source
23.2.1 Secondary Sources
23.2.2 Primary Sources
23.3 Disclaimer
Electronic and Semiconductor
Food and Beverages
Chemicals and Materials
Consumer Goods
Construction Manufacturing
Aerospace and Defence
Energy and Power
ICT Media
Banking and Finance
Automotive and Transportation
Machinery and Equipments
Pharmaceutical and Healthcare
Medical Devices